跳至主要内容
临床试验/CTRI/2019/04/018781
CTRI/2019/04/018781已完成未知

Oral vs IV sildenafil in persistent pulmonary hypertension of newborn (PPHN) : A randomized controlled pilot study

Bharati Hospital0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Late preterm and term neonates who are echocardiographicaly diagnosed to have PPHN (defined as PAP of more than 25 millimetre of mercury (mm Hg)),
  • PPHN diagnosed within 72 hrs of life

排除标准

  • Congenital heart disease (Except patent ductus arteriosus, patent foramen ovale, atrial septal defect, or a single, small muscular ( <4 mm) ventricular septal defect);
  • Contraindication to oral/IV sildenafil ââ?¬â?? systemic hypotension, necrotizing enterocolitis (NEC), Gastrointestinal bleed;
  • Congenital diaphragmatic hernia;
  • Lethal congenital anomaly;
  • Babies with severe PPHN directly started on nitric oxide on diagnosis

研究者

发起方
Bharati Hospital

相似试验